Mild cognitive impairment and Alzheimer disease have a low prevalence among newly diagnosed patients with multiple sclerosis.

Cladribine treatment for relapsing multiple sclerosis improves health-related quality of life and preserves cognitive function after 4 years.

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

Children with pediatric-onset multiple sclerosis (POMS) have shorter telomeres, suggesting MS may accelerate biological aging.

Credit: Getty Images In an interim analysis of ENLIGHTEN, researchers described changes in cognitive function over 1 year in patients with MS. For the Symbol Digit Modalities Test, clinically ...

Credit: Getty Images Presenting at ACTRIMS 2025, researchers reported on the safety and clinical efficacy over 24 months of patients with relapsing multiple sclerosis switching to cladribine from ...

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

Ocrelizumab treatment in Black and Hispanic patients with MS reduces NfL levels and prevents the forming of contrast-enhancing lesions and new or enlarging T2 lesions.

Higher ocrelizumab doses improve the benefit-risk profile among patients with relapsing multiple sclerosis treated with it for up to 10 years.